Close Menu

This week in the PNAS Early Edition, researchers at the Washington University School of Medicine show that LRP6 silencing in breast cancer cells reduces Wnt signaling, cell proliferation, and tumor growth. Their results suggest that an LRP6 antagonist, Mesd, is a promising antitumor agent and potential therapeutic target for breast cancer subtypes with Wnt activation at the cell surface.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.